A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.
作者： Young Kwang Chae , Lauren Chiec , Nisha Mohindra , Ryan Gentzler , Jyoti Patel
DOI: 10.1007/S00262-016-1913-7
关键词:
摘要: Immune checkpoint inhibitors such as pembrolizumab, ipilimumab, and nivolumab, now FDA-approved for use in treating several types of cancer, have been associated with immune-related adverse effects. Specifically, the antibodies targeting programmed-cell death-1 immune checkpoint, pembrolizumab rarely reported to induce development type 1 diabetes mellitus. Here we describe a case patient who developed antibody-positive mellitus following treatment combination systemic chemotherapy metastatic adenocarcinoma lung. We will also provide brief literature review other cases presenting after well discussion regarding potential mechanisms this effect its importance these drugs continue become even more widespread.
springer.com
sci-hub.se 参考文章(33)
Caroline Gaudy, Céline Clévy, Sandrine Monestier, Noémie Dubois, Yanis Préau, Stéphanie Mallet, Marie-Aleth Richard, Jean-Jacques Grob, René Valéro, Sophie Béliard, Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes Diabetes Care. ,vol. 38, ,(2015) , 10.2337/DC15-1331
Jiabei He, Ying Hu, Mingming Hu, Baolan Li, None, Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer Scientific Reports. ,vol. 5, pp. 13110- 13110 ,(2015) , 10.1038/SREP13110
Valentina Perri, Benedetta Russo, Antonino Crinò, Riccardo Schiaffini, Ezio Giorda, Marco Cappa, Maria Rosado, Alessandra Fierabracci, Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus. International Journal of Molecular Sciences. ,vol. 16, pp. 22584- 22605 ,(2015) , 10.3390/IJMS160922584
D. M. Sansom, CD28, CTLA-4 and their ligands: who does what and to whom? Immunology. ,vol. 101, pp. 169- 177 ,(2000) , 10.1046/J.1365-2567.2000.00121.X
Tomoya Kawazoe, Manabu Araki, Youwei Lin, Masafumi Ogawa, Tomoko Okamoto, Takashi Yamamura, Masato Wakakura, Miho Murata, New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C. Internal Medicine. ,vol. 51, pp. 2625- 2629 ,(2012) , 10.2169/INTERNALMEDICINE.51.7771
Masanori Yamazaki, Ai Sato, Teiji Takeda, Mitsuhisa Komatsu, Distinct Clinical Courses in Type 1 Diabetes Mellitus Induced by Peg-interferon-.ALPHA. Treatment for Chronic Hepatitis C Internal Medicine. ,vol. 49, pp. 403- 407 ,(2010) , 10.2169/INTERNALMEDICINE.49.2656
Teruo Shiba, Yoshihiro Morino, Kazumi Tagawa, Hitoshi Fujino, Tadao Unuma, Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis Diabetes Research and Clinical Practice. ,vol. 30, pp. 237- 241 ,(1995) , 10.1016/0168-8227(95)01188-9
Janelle A. Noble, Ana M. Valdes, Genetics of the HLA region in the prediction of type 1 diabetes. Current Diabetes Reports. ,vol. 11, pp. 533- 542 ,(2011) , 10.1007/S11892-011-0223-X
Le Min, Nageatte Ibrahim, Ipilimumab-induced autoimmune adrenalitis. The Lancet Diabetes & Endocrinology. ,vol. 1, ,(2013) , 10.1016/S2213-8587(13)70031-7
Qing Li, Hugh O. McDevitt, The role of interferon alpha in initiation of type I diabetes in the NOD mouse. Clinical Immunology. ,vol. 140, pp. 3- 7 ,(2011) , 10.1016/J.CLIM.2011.04.010